Jagsonpal Pharmaceuticals Limited has informed the Exchange about Buyback Letter of Offer

Buyback Premium Above 10pctCorporate Actions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹210.00

prior close

₹210.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%+0.5% vs market

Pharmaceuticals peers, median of 165sector+0.4%+1.6% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.5

15m

-0.6

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0+1.6+0.5+0.4+1.6

Next day

+3.5+1.5+2.0+0.5+3.0

-0.5+0.0-0.6+0.7-1.3

+1.0-3.0+4.0-1.0+2.0

+0.2-2.4+2.6-1.4+1.7

-1.7-2.1+0.5-0.5-1.1

-5.3-3.8-1.4-1.7-3.6

15d

-1.9-0.0-1.9+1.1-3.0

-6.0-1.0-5.0-0.6-5.4

+13.8+6.5+7.3+4.1+9.7

+10.2+10.2+0.1+6.1+4.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals Limited has announced a buyback of up to 16,00,000 equity shares (2.38% of total paid-up capital) at ₹250 per share, for a total consideration up to ₹40 crores. The buyback runs from May 8 to May 14, 2026, via the tender offer route through BSE. The offer price represents a significant premium over the face value of ₹2 per share. Shareholders can tender their shares proportionally, with small shareholders getting a reserved category allocation. The buyback size is 18.35% of the company's aggregate paid-up capital and free reserves as per FY2025, within the statutory 25% limit. Settlement is scheduled for May 21, 2026.

Likely market impact

The buyback offers shareholders an opportunity to exit at ₹250 per share, with the company returning capital. The high buyback price relative to face value suggests significant premium, which could support the stock price near the offer price during the tender period.